Martinsried/Munich, April 7, 2008. Today MediGene AG (Frankfurt, Prime Standard: MDG) presented the detailed efficacy data of the company’s drug candidate EndoTAG(TM)-1, obtained in a controlled clinical phase II trial for the treatment of pancreatic carcinoma. In this extensive trial, EndoTAG(TM)-1 provides a clear survival advantage compared with the approved standard drug gemcitabine. For the first time the novel mode of action of EndoTAG(TM)-1 is proved, which is targeted at “starving out” tumors by selective destruction of tumor blood vessels. This means that EndoTAG(TM)-1 could also be suited for the treatment of all solid, highly vascularized types of tumors, providing multiple therapeutic options and a sales potential of billions of Euros for our company.
